ASML
ASML Holding N.V.
ASML's fundamentals are strong: revenue grew 30% and its operating margin rose 5 points to 39%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ASML Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Strong | |
| Strong |
ASML's profitability, cash flow and balance sheet are currently strong. There isn't enough data to rate its revenue.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ASML PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 35x | $1,375 | -8.2% |
| Current | 39x | $1,497 | — |
| Fair | 43x | $1,684 | +13% |
| Expensive | 56x | $2,177 | +45% |
Historical ranges are pointers, not guarantees.
ASML's PE is 39x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ASML Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
ASML has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ASML Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $38.88 | +44% |
| Q2 2026 | $30.61 | +15% |
| Q3 2025 | $26.91 | +38% |
| Q2 2025 | $26.68 | +40% |
| Q1 2025 | $24.60 | +22% |
| Q4 2024 | $21.42 | -2.9% |
| Q3 2024 | $19.46 | -8.4% |
| Q2 2024 | $19.11 | -7.5% |
ASML has the stronger earnings trend. Trailing diluted EPS is up 58% for ASML versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ASML Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13B | +55% |
| Q2 2026 | $10.4B | +21% |
| Q1 2026 | $9.7B | +13% |
| Q4 2025 | $10.8B | +4.9% |
| Q3 2025 | $8.3B | +0.7% |
| Q3 2025 | $8.3B | +0.7% |
| Q2 2025 | $8.5B | +23% |
| Q1 2025 | $8.6B | +46% |
ASML's revenue has grown year over year for four quarters in a row: $13B last quarter, up 55% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 44% | +12 points |
| Q2 2026 | 37% | +4.2 points |
| Q1 2026 | 36% | +1.4 points |
| Q4 2025 | 35% | -0.1 points |
| Q3 2025 | 33% | -3.4 points |
| Q3 2025 | 33% | +0.2 points |
| Q2 2025 | 35% | +5.3 points |
| Q1 2025 | 35% | +9.1 points |
ASML has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ASML on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ASML Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $12.6B | +4571% |
| Q2 2026 | $1.6B | +292% |
| Q1 2026 | -$2.9B | -$2.4B |
| Q4 2025 | $12.2B | +24% |
| Q3 2025 | $270.7M | -54% |
| Q3 2025 | $270.7M | -54% |
| Q2 2025 | $397.4M | -10% |
| Q1 2025 | -$527.8M | +$223M |
ASML generated $23.5B in free cash flow over the past year, more than ten times what it generated the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ASML on cash flow, with more consistent year-over-year improvement.
ASML Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -1.4M shares |
| 1 year | -1.1% | -4.1M shares |
| 3 years | -2.6% | -10.3M shares |
| 5 years | -5.3% | -21.5M shares |
| Available history | -8.6% | -36.2M shares |
ASML has 384M diluted shares, down 1.1% from a year ago, with $8.7B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.5B |
| Q2 2026 | $1.2B |
| Q1 2026 | $1.1B |
| Q4 2025 | $1.9B |
| Q3 2025 | $191.3M |
| Q3 2025 | $191.3M |
| Q2 2025 | $1.6B |
| Q1 2025 | $2.9B |
ASML spent $8.7B buying back its own shares over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ASML on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ASML Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.4x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -0.3x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | -0.8x | Net Cash |
| Q3 2024 | -0.0x | Net Cash |
| Q2 2024 | -0.0x | Net Cash |
ASML has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ASML Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.5 | Neutral |
| Stochastic | 16.3 | Oversold |
ASML's weekly RSI is 44 (neutral) and its Stochastic is 16 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ASML PE vs Technology Sector
| Metric | ASML | Sector median | Relative |
|---|---|---|---|
| PE | 39x | 28x | 38% above |
| PE % | 30 | 35 | 5 pts below |
ASML is trading at 39x earnings, a 38% premium to the Technology sector's median of 28x, though its earnings don't support one.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ASML Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,636.6 | 8.5% below |
| 20 week MA | $1,696.6 | 12% below |
| 50 week MA | $1,531.1 | 2.2% below |
| 100 week MA | $1,160.1 | 29% above |
| 200 week MA | $964.4 | 55% above |
ASML has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ASML Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.7 | $483.1 | +63% |
| 2021 | $483.1 | $801.4 | +66% |
| 2022 | $801.4 | $551.4 | -31% |
| 2023 | $551.4 | $756.9 | +37% |
| 2024 | $756.9 | $713.6 | -5.7% |
| 2025 | $713.6 | $1,072.8 | +50% |
| 2026 YTD | $1,072.8 | $1,497.1 | +40% |
ASML has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.